Dr. Bunn is Distinguished Professor of Medicine and the James Dudley endowed Professor of Lung Cancer research at the University of Colorado Cancer Center and School of Medicine. He is also Director of the University of Colorado Comprehensive Cancer Center. He has been President of American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association of Cancer Institutes (AACI). He has served as Chairman of the FDA Oncology Drug Advisory Committee and Executive Director of the IASLC.
His major interest is novel therapies for the early detection and prevention of lung cancer. His studies have set standards for the treatment of lung cancer; they have identified issues of natural history and biomarkers to aid in prognosis and therapy selection.
W. Jeffery Edenfield, MD brings to Inteliquet more than 25 years of expertise in all aspects of clinical oncology, including translational oncology research, cancer care and care delivery. As the CMO, he works to enhance Inteliquet’s platform, so that it can contribute to improved outcomes through personalized treatment for patients needing access to clinical trials.
Dr. Edenfield is Medical Director at the Institute for Translational Oncology Research (ITOR) at Greenville Health System (GHS) Cancer Institute, which advances care on multiple levels, including facilitating pioneering research and clinical care delivery. He oversees phase I and first-in-human clinical trials for new cancer medications and manages its Biorepository Services.
Dr. Edenfield is board certified in Medical Oncology and Hematology. He is also certified in Hospice and Palliative Medicine. He has published numerous peer-reviewed articles and has been a national principal investigator for phase l, ll, and lll oncology trials. He is a member of the American Society of Clinical Oncology and is the Academic Vice Chair for Oncology in the Greenville Health System, where he is currently an Associate Professor in the Department of Medicine. His extensive experience in the application of genomic information on patient care has driven a focus on enabling patients with access to quality clinical trials.
Dr. Edenfield earned his Medical Degree from the University of Miami, Florida. He completed his internship, residency, and fellowship at Walter Reed Army Medical Center in Washington, D.C. Dr. Edenfield also completed a research fellowship in Hematologic Malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his active duty service obligation, obtaining the rank of Major, as Chief of Oncology at Womack Army Medical Center in North Carolina.
“I am hopeful about the many new treatments emerging for my patients. Every day there are new pathways of drug approval, which are accelerating the options for keeping them well. However, we are reaching only a small fraction of patients with respect to clinical trial enrollment. With hundreds of new drugs needing to be studied, innovative methods to inform physicians and match patients to these trials have never been more important. Doubling the number of adults who join oncology clinical trials from three percent to six percent would be a tremendous accomplishment, and Inteliquet is uniquely positioned to move us in that direction.”
Dr. Hahn is Associate Professor of Medicine at the Department of Oncology and the Department of Urology at Johns Hopkins University School of Medicine. He also is Director of the Medical Oncology Bladder Cancer Program. He also serves as the Bladder Cancer Committee Chair of the Eastern Cooperative Oncology Group (ECOG), participates in the National Cancer Institute’s Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network.
Dr. Hahn is an internationally recognized authority in the conduct of bladder cancer novel therapeutic clinical trials and translational investigations.
Dr. Hamilton is a gastrointestinal and molecular pathologist, and Professor and Head of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center (UTMDACC). He is an active member of the Eastern Cooperative Oncology Group and has published studies about the molecular pathology of colorectal cancer. He also has served as the Principal Investigator of the Cancer Center Support Grant-sponsored Tissue Biorepository and Pathology Resource core facility since 1998.
Dr. Hamilton’s area of interest includes developing biomarkers that help with the prognosis and prediction of the response to therapy that can improve patient survival and quality of life.